Using omega-3 fatty acids in the practice of clinical lipidology

Journal of Clinical Lipidology

Volumn 5, Issue 6, 2011, Pages 424-433

  Brown, W Virgil ^a   Bays, Harold ^b   Harris, William ^c   Miller, Michael ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^c Health Diagnostic Laboratory Inc   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKR 963; AMR 101; DOCOSAHEXAENOIC ACID; EPANOVA; FIBRIC ACID DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; OMEGA 3 FATTY ACID ESTER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; CANCER RISK; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG CAPSULE; DRUG COST; DRUG FORMULATION; DRUG INDICATION; DRUG MARKETING; DRUG TOLERABILITY; FISH; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; MORTALITY; NOTE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 81855170195     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.09.006     Document Type: Review

References (29)

1. H. Bays Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians Drugs Today 44 2008 205 246 (Pubitemid 351669107)
2. Bays HE, Ballantyne CM, Kastelein JJ, et al. AMR101, a pure-EPA omega-3 fatty acid, lowers triglycerides in patients with very high triglycerides without raising LDL-C: the MARINE study. Poster/Abstract presented at the National Lipid Association. May 19-22, 2011. New York, New York.
3. H.E. Bays, C.M. Ballantyne, J.J. Kastelein, J.L. Issacsohn, R.A. Braeckman, and P.N. Soni Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multicenter, placebo-controlled, Randomized, double-blind, 12-week study with an open-label extension [MARINE] trial) Am J Cardiol 108 2011 682 690
4. Bays HE, Ballantyne CM, Kastelein JJ, et al. AMR101, a pure-EPA omega-3 fatty acid, lowers triglycerides in patients with very high triglycerides without raising LDL-C: the MARINE study. European Society of Cardiology. Podium/Oral presentation. August 29, 2011 Paris France.
5. Davidson MH, Johnson J, Rooney MW, Kling DF. Omega-3 free fatty acids demonstrate more than 4-fold greater bioavailability for EPA and DHA compared to Omega-3-acid ethyl esters in conjunction with a low fat diet: The ECLIPSE Study. Poster/Abstract presented at the National Lipid Association. May 19-22, 2011. New York, New York.
6. Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia. ClinicalTrials.gov website. Available at: http://clinicaltrials.gov/ct2/results? term=trygg. Accessed August 7, 2011.
7. Niaspan® Prescribing Information. Available at: http://www.rxabbott. com/pdf/niaspan.pdf. Accessed August 7, 2011.
8. H.E. Bays, E.M. Roth, and J.M. McKenney The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia Diabetes Care 33 2010 2113 2116
9. E.M. Roth, H.E. Bays, and A.D. Forker Prescription omega-3 fatty acid as an adjuct to fenofibrate therapy in hypertriglyceridemic subjects J Cardiovasc Pharmacol 54 2009 196 203
10. D. Brisson, J. Methot, and K. Tremblay Comparison of efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics Pharmacogenet Genomics 20 2010 742 747
11. H.E. Bays Safety considerations with omega-3 fatty acid therapy Am J Cardiol 99 suppl 2007 35C 43C
12. H.E. Bays, K.C. Maki, R.T. Doyle, and E. Stein The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels Postgrad Med 121 2009 145 150
13. M.H. Davidson, E.A. Stein, and H.E. Bays Efficacy and tolerability of adding prescription omega-3 fatty acids 4g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 29 2007 1354 1367 (Pubitemid 47348116)
14. Lovaza prescribing Information. Available at: http://us.gsk.com/products/ assets/us-lovaza.pdf. Accessed August 7, 2011.
15. H.E. Bays Safety considerations with omega-3 fatty acid therapy Am J Cardiol 99 suppl 2007 35C 43C
16. P.M. Kris-Etherton, W.S. Harris, and L.J. Appel Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Circulation 106 2002 2747 2757 (Pubitemid 35364932)
17. W.S. Harris, D. Mozaffarian, and E.B. Rimm Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Committee Circulation 119 2009 902 907
18. W.S. Harris, D. Mozaffarian, and M. Lefevre Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids J Nutr 139 2009 804S 819S
19. D. Mozaffarian, and E.B. Rimm Fish intake, contaminants, and human health: evaluating the risks and the benefits JAMA 296 2006 1885 1899 (Pubitemid 44596197)
20. R. Marchioli, F. Barzi, and E. Bomba Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione Circulation 105 2002 1897 1903 (Pubitemid 34437615)
21. M. Yokoyama, H. Origasa, and M. Matsuzaki Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098 (Pubitemid 46483662)
22. R. De Caterina n-3 fatty acids in cardiovascular disease N Engl J Med 364 2011 2439 2450
23. W.S. Harris The omega-3 index: clinical utility for therapeutic intervention Curr Cardiol Rep 12 2010 503 508
24. S. Nodari, M. Triggiani, and U. Campia Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy J Am Coll Cardiol 57 2011 870 879
25. M. Miller, N.J. Stone, C. Ballantyne on behalf of the American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, and Council on the Kidney in Cardiovascular Disease Triglycerides and Cardiovascular Disease: A Scientific Statement from the American Heart Association Circulation 123 2011 2292 2333
26. W. Harris, M. Miller, A.P. Tighe, M. Davidson, and E. Schaefer Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives Atherosclerosis 197 2008 12 24
27. T. Jacobson, M. Miller, and E. Schaefer Hypertriglyceridemia and cardiovascular risk reduction Clin Ther 29 2007 763 777 (Pubitemid 47232327)
28. M. Miller, H.N. Ginsberg, and E. Schaefer Relative atherogenicity and predictive value of non-high density lipoprotein cholesterol for coronary heart disease Am J Cardiol 101 2008 1003 1008
29. E. Balk, M. Chung, and A. Lichtenstein Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease Evid Rep Technol Assess (Summ) 93 2004 1 6